Stockreport

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates [Yahoo! Finance]

Tarsus Pharmaceuticals, Inc.  (TARS) 
PDF Revenues of US$17m beat estimates by a substantial 80% margin. Unfortunately, Tarsus Pharmaceuticals also reported a statutory loss of US$4.62 per share, which at least [Read more]